VR Adviser as of Dec. 31, 2020
Portfolio Holdings for VR Adviser
VR Adviser holds 25 positions in its portfolio as reported in the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Constellation Pharmceticls I | 17.0 | $116M | 4.0M | 28.80 | |
| Olema Pharmaceuticals (OLMA) | 10.9 | $74M | 1.5M | 48.08 | |
| Trillium Therapeutics, Inc. Cmn | 8.7 | $59M | 4.0M | 14.71 | |
| Kinnate Biopharma (KNTE) | 8.6 | $59M | 1.5M | 39.78 | |
| Athira Pharma (ATHA) | 8.5 | $58M | 1.7M | 34.25 | |
| Altimmune (ALT) | 7.5 | $51M | 4.5M | 11.28 | |
| Keros Therapeutics (KROS) | 7.0 | $47M | 672k | 70.54 | |
| Marinus Pharmaceuticals (MRNS) | 4.6 | $32M | 2.6M | 12.20 | |
| Syndax Pharmaceuticals (SNDX) | 3.6 | $25M | 1.1M | 22.24 | |
| Relmada Therapeutics (RLMD) | 3.2 | $21M | 668k | 32.07 | |
| Kura Oncology (KURA) | 2.8 | $19M | 575k | 32.66 | |
| Vistagen Therapeutics | 2.7 | $18M | 9.4M | 1.94 | |
| Celldex Therapeutics (CLDX) | 2.1 | $14M | 800k | 17.52 | |
| Surface Oncology | 2.0 | $13M | 1.4M | 9.24 | |
| Aclaris Therapeutics (ACRS) | 1.9 | $13M | 2.0M | 6.47 | |
| Cogent Biosciences (COGT) | 1.8 | $12M | 1.1M | 11.23 | |
| Aligos Therapeutics (ALGS) | 1.6 | $11M | 405k | 27.65 | |
| Galera Therapeutics (GRTX) | 1.4 | $9.4M | 918k | 10.23 | |
| Silverback Therapeutics (SPRY) | 1.0 | $7.0M | 150k | 46.34 | |
| Bctg Acquisition Corp | 0.8 | $5.7M | 500k | 11.44 | |
| Metacrine Ord | 0.8 | $5.5M | 694k | 7.86 | |
| Five Prime Therapeutics | 0.6 | $4.2M | 245k | 17.01 | |
| Bioatla (BCAB) | 0.5 | $3.4M | 100k | 34.01 | |
| Taysha Gene Therapies Com Shs (TSHA) | 0.4 | $2.9M | 108k | 26.54 | |
| Miragen Therapeutics (VRDN) | 0.0 | $321k | 20k | 16.47 |
